Streptococcus pneumoniae: Resistance update and treatment options

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Streptococcus pneumoniae is a major worldwide bacterial pathogen responsible for a variety of infections including pneumonia, bacteremia, otitis media, meningitis, sinusitis, and other infections. It is the most common pathogen causing bacterial community-acquired pneumonia (CAP) (1). Pneumococcal pneumonia has always been responsible for significant morbidity and mortality. In the pre-antibiotic era, it carried a 25% to 35% case fatality rate, which increased to 80% if bacteremia was present (2). Following the introduction of penicillin, mortality rates were reduced to below 10% (3). Sixty years later, mortality rates still remain around 12% for all hospitalized patients (1) and up to 25% for those with bacteremia (1,4). The continued significant mortality of pneumococcal disease despite the advances in antimicrobial therapy and intensive care management over the past half-century underscores the innate pathogenicity of this organism.

Original languageEnglish (US)
Title of host publicationAntimicrobial Resistance
Subtitle of host publicationProblem Pathogens and Clinical Countermeasures
PublisherCRC Press
Pages111-124
Number of pages14
ISBN (Electronic)9781420017236
ISBN (Print)9780824729417
StatePublished - Jan 1 2007

Fingerprint

Streptococcus pneumoniae
Bacteremia
Mortality
Pneumonia
Pneumococcal Pneumonia
Therapeutics
Sinusitis
Otitis Media
Critical Care
Infection
Meningitis
Penicillins
Virulence
Anti-Bacterial Agents
Morbidity

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Akar, N., Bishai, W. R., & Jain, S. (2007). Streptococcus pneumoniae: Resistance update and treatment options. In Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures (pp. 111-124). CRC Press.

Streptococcus pneumoniae : Resistance update and treatment options. / Akar, Nicole; Bishai, William Ramses; Jain, Sanjay.

Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures. CRC Press, 2007. p. 111-124.

Research output: Chapter in Book/Report/Conference proceedingChapter

Akar, N, Bishai, WR & Jain, S 2007, Streptococcus pneumoniae: Resistance update and treatment options. in Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures. CRC Press, pp. 111-124.
Akar N, Bishai WR, Jain S. Streptococcus pneumoniae: Resistance update and treatment options. In Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures. CRC Press. 2007. p. 111-124
Akar, Nicole ; Bishai, William Ramses ; Jain, Sanjay. / Streptococcus pneumoniae : Resistance update and treatment options. Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures. CRC Press, 2007. pp. 111-124
@inbook{892bd3897a9b4d4795ef6c56c2b7cca5,
title = "Streptococcus pneumoniae: Resistance update and treatment options",
abstract = "Streptococcus pneumoniae is a major worldwide bacterial pathogen responsible for a variety of infections including pneumonia, bacteremia, otitis media, meningitis, sinusitis, and other infections. It is the most common pathogen causing bacterial community-acquired pneumonia (CAP) (1). Pneumococcal pneumonia has always been responsible for significant morbidity and mortality. In the pre-antibiotic era, it carried a 25{\%} to 35{\%} case fatality rate, which increased to 80{\%} if bacteremia was present (2). Following the introduction of penicillin, mortality rates were reduced to below 10{\%} (3). Sixty years later, mortality rates still remain around 12{\%} for all hospitalized patients (1) and up to 25{\%} for those with bacteremia (1,4). The continued significant mortality of pneumococcal disease despite the advances in antimicrobial therapy and intensive care management over the past half-century underscores the innate pathogenicity of this organism.",
author = "Nicole Akar and Bishai, {William Ramses} and Sanjay Jain",
year = "2007",
month = "1",
day = "1",
language = "English (US)",
isbn = "9780824729417",
pages = "111--124",
booktitle = "Antimicrobial Resistance",
publisher = "CRC Press",
address = "United States",

}

TY - CHAP

T1 - Streptococcus pneumoniae

T2 - Resistance update and treatment options

AU - Akar, Nicole

AU - Bishai, William Ramses

AU - Jain, Sanjay

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Streptococcus pneumoniae is a major worldwide bacterial pathogen responsible for a variety of infections including pneumonia, bacteremia, otitis media, meningitis, sinusitis, and other infections. It is the most common pathogen causing bacterial community-acquired pneumonia (CAP) (1). Pneumococcal pneumonia has always been responsible for significant morbidity and mortality. In the pre-antibiotic era, it carried a 25% to 35% case fatality rate, which increased to 80% if bacteremia was present (2). Following the introduction of penicillin, mortality rates were reduced to below 10% (3). Sixty years later, mortality rates still remain around 12% for all hospitalized patients (1) and up to 25% for those with bacteremia (1,4). The continued significant mortality of pneumococcal disease despite the advances in antimicrobial therapy and intensive care management over the past half-century underscores the innate pathogenicity of this organism.

AB - Streptococcus pneumoniae is a major worldwide bacterial pathogen responsible for a variety of infections including pneumonia, bacteremia, otitis media, meningitis, sinusitis, and other infections. It is the most common pathogen causing bacterial community-acquired pneumonia (CAP) (1). Pneumococcal pneumonia has always been responsible for significant morbidity and mortality. In the pre-antibiotic era, it carried a 25% to 35% case fatality rate, which increased to 80% if bacteremia was present (2). Following the introduction of penicillin, mortality rates were reduced to below 10% (3). Sixty years later, mortality rates still remain around 12% for all hospitalized patients (1) and up to 25% for those with bacteremia (1,4). The continued significant mortality of pneumococcal disease despite the advances in antimicrobial therapy and intensive care management over the past half-century underscores the innate pathogenicity of this organism.

UR - http://www.scopus.com/inward/record.url?scp=85057485662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057485662&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85057485662

SN - 9780824729417

SP - 111

EP - 124

BT - Antimicrobial Resistance

PB - CRC Press

ER -